Bradykinin and the Pathogenesis of Hereditary Angioedema by Allen P. Kaplan
NOTES OF ALLERGY WATCHERS
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Hereditary angioedema (HAE) is a term coined for afamilial form of potentially life-threatening angioedema
first described by William Osler in 1888. It is inherited as an
autosomal dominant and the older literature often employs
the term angioneurotic edema because it was believed that
swelling could be a consequence of an emotional disorder.
This type of angioedema, in particular, often included family
histories of death by asphyxiation so that family members
appeared “neurotic,” that is, overly fearful, anxious, de-
pressed, and so on. It also turns out that episodes of angio-
edema may well be triggered by emotional events in addition
to other known triggers such as trauma, infection, and estro-
gen-containing hormones, but the biochemical explanation
for this is not yet known. However, the conception of the
disorder changed in 1953 when Donaldson and Evans dis-
covered that it is due to a mutation in a plasma enzyme
inhibitor known as C1 inhibitor (C1 INH).1 It was then
assumed that some vasoactive mediator from the complement
system was the proximate cause of the angioedema.
The next era dealt with attempts to identify this vaso-
active factor. It then became clear that his inhibitor could
inactivate enzymes that are not part of the complement
cascade. The first discovery was that it inhibited plasma
kallikrein,2 an enzyme that cleaves a plasma kininogen to
produce bradykinin. At that point, no one seriously consid-
ered bradykinin as a possible cause of the swelling. The focus
was on a kinin thought to be derived from the complement
cascade termed C2 kinin. The key experiment, published in a
nonrefereed journal,3 was that activated C1 will cleave C2 (in
the presence of C4 as a cofactor) to yield C2a C2b, and that
plasmin digestion of C2b would produce a kinin that could be
distinguished from bradykinin by its inactivation by tryptic
digestion. It could be assayed by contraction of an estrous rat
uterus or with lesser sensitivity (but greater reliability), em-
ploying a guinea pig ileum. This observation was never
confirmed by other workers but additional observations
seemed to substantiate the idea. Studies of vascular permea-
bility in human and rabbit skin indicated that injection of
activated C1 led to increased vascular permeability that
required C2; the swelling was augmented when skin testing
of patients with hereditary angioedema was compared with
normal controls.4 There was even one publication by Don-
aldson5 suggesting a linkage between activated Factor XII
(activated Hageman factor) and activation of the complement
cascade so that simultaneous production of bradykinin (inhibited
by Factor XII activation) and the C2-kinin seemed possible.
During the years 1972–1990 I was studying the mech-
anism of activation of the plasma bradykinin cascade. Two
forms of activated Factor XII were described, that is, Factor
XIIa at about 80 kd and Factor XII fragment (XIIf) at 28.5–30
kd6,7; soon thereafter, the Factor XII native protein was
purified.8 Factor XIIa or Factor XIIf was shown to be re-
quired for kallikrein activity to be produced in plasma;
prekallikrein was purified,9 and its mechanism of conversion
to kallikrein described. A controversy regarding the number
of kininogens in plasma was resolved to indicate that there is
a high molecular weight kininogen (HK) that is rather selec-
tively cleaved by plasma kallikrein10,11 to yield bradykinin,
whereas low molecular weight kininogen is preferentially
cleaved by tissue kallikrein to produce lysylbradykinin (kal-
lidin). About 80% of plasma kallikrein was found to circulate
as a complex with HK12 and the distal light chain segment of
HK was shown to be the feature that distinguishes it from low
molecular weight kininogen (LK). This HK domain has the
site of prekallikrein binding13,14 and the site responsible for
the cofactor activity of HK, which accelerates the conversion
of prekallikrein to kallikrein and also conversion of coagula-
tion factor XI to factor XIa.14 Activation of the bradykinin-
forming cascade was known to occur upon binding to nega-
tively charged surfaces (eg, a glass test tube to clot blood) and
this acceleration by surface binding was studied in some
detail.15,16 Factor XII was shown to autoactivate upon bind-
ing17 so a molecular mechanism for initiation of the cascade
seemed to be in place. From the onset of these studies, in the
late 1970s, I was of the opinion that bradykinin is the
mediator of the swelling seen in hereditary angioedema and
that C2 kinin might be an artifact. My bias was based on a
conversation with Frank Austen that occurred when the C2
kinin data were presented at a plenary session of The Asso-
ciation of American Physicians and I was seated in the
audience. A rat uterus–based bioassay was used to demon-
strate the new kinin and I had been trying to use such an assay
to measure bradykinin for months. Its baseline was poor, it
contracted when agonist (any agonist, at times including the
buffer control) was added to the bath solution, and I could not
be sure what was real and what was not. I switched to using
a guinea pig ileum. I looked at the data being presented, I
turned to Frank Austen, who was sitting next to me, and
exclaimed, “That’s an artifact!” I could not, however, explain
the C2–dependent increase in vascular permeability reported
by skin testing and am not sure I could do so even now. One
issue is that anything injected into hereditary angioedema
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skin will produce bradykinin because of the trauma. It was by
then clear that all enzymes required for the production of
bradykinin are inhibited by C1 inhibitor18 and that active
kallikrein was demonstrable within induced blisters of HAE
patients.19
Nevertheless, in 1983 I decided to try to reproduce
these experiments demonstrating plasmin cleavage of C2a or
C2b to generate a kinin-like molecule. We activated C1 by
immune complexes in the presence of C4 and C2, added
plasmin, and could not demonstrate any kinin.20 By contrast,
incubation of HAE plasma, collected in EDTA to inhibit
kininases, generated increasing amounts of bradykinin even
in the absence of an initiating surface,20 whereas normal
plasma generated nothing. Thus, plasma deficient in C1
INH was unstable and activated seemingly spontaneously
to generate bradykinin upon in vitro incubation. We con-
cluded that C2-kinin is not present, implied that it does not
exist, and stated that bradykinin is the likely mediator of
swelling in HAE. A subsequent publication found a 25
amino acid peptide with permeability increasing properties
within the C2 amino acid sequence, but it is not released by
any known peptide.21
Because C2-kinin and bradykinin were the only 2
possibilities considered as possible mediators of the swelling
of HAE and the data upon which C2-kinin was based could
not be reproduced, bradykinin would be the “answer.” But
not being mathematicians (who accept disproving 1 of 2
possible choices as answering the question), this conclusion
was not accepted until an additional 15 years passed, even
after the nonexistence of C2-kinin was confirmed by a second
study.22 Finally, years later bradykinin was accepted to be the
cause of the swelling of HAE after the following studies were
reported.1 A confirmation of our 1983 paper demonstrated
that bradykinin is the only vasoactive kinin generated in HAE
plasma assayed by vascular permeability or radioimmunoas-
say and anti-C2 could not prevent the phenomenon.23,2 A
rodent model in which C1 INH was knocked could be
“cured” not only by repleting the C1 INH but also by
knocking out the bradykinin B-2 receptor.24,3 Bradykinin
levels are elevated locally at the site of swelling in HAE.25,4
A unique family in which a mutation of C1 INH renders it
inactive on activated C1 but normally active as an inhibitor of
the enzymes of the bradykinin-forming cascade (ie, Factor
XIIa, Factor XIIf, and kallikrein) has no episodes of angio-
edema in any family members.26 Curiously, review articles
during this period often mentioned C2-kinin as a viable
alternative to bradykinin as the key mediator, and I wrote an
editorial entitled “Does C2-kinin exist,” indicating, in detail,
why it does not.27 Until someone else shows it existence, and
that it has some role in HAE based on experimental evidence,
it should not be mentioned in anything but an historical
context and it should certainly not be included in diagrams
dealing with the pathogenesis of HAE.
The notion that bradykinin is the mediator of HAE has
lead to therapeutic advances that specifically target the Factor
XII-prekallikrein HK-bradykinin cascade. Of course, replet-
ing C1 INH by infusion can be employed to control acute
episodes of swelling and for prophylaxis.28 When prophylaxis
is considered, C1 INH infusion may replace attenuated an-
drogens primarily because it eliminates the possibility of
cumulative androgen side effects, although it is far more
costly. C1 INH does require intravenous infusion but having
home access to treatment is an important step forward.
Perhaps a subcutaneous preparation will be seen in the future
as has occurred with intravenous immunoglobulin. Therapy
for acute episodes of swelling now include ecallantide, a
plasma kallikrein inhibitor,29 and Icatibant,30 a B-2 brady-
kinin receptor antagonist. These have a short half-life and
therefore cannot be used for prophylaxis. They are adminis-
tered subcutaneously and can be repeated within an hour
should control of symptoms be suboptimal. Both are quite
effective, particularly if given early at the onset of an episode,
and can abort symptoms of peripheral angioedema, gastroin-
testinal attacks, and laryngeal edema. At present, ecallantide
is approved in the United States and Icatibant is approved in
Europe. The efficacy of these drugs add to the cumulative
data demonstrating this bradykinin-forming cascade as the
one responsible for symptoms despite the fact that the com-
plement is activated. In fact, C1 is unstable in the absence of
C1 INH so that C4 is continually being cleaved, and if
synthesis does not keep up, a low C4 level will result. Thus,
quantitation of C4 is a good screening determination, along
with measurement of C1 INH by protein and function C4 is
low 95% of the time in HAE patients who are asymptomatic;
C2 remains normal. However, during an attack of swelling
formation of Factor XIIf31 directly activates the C1r subcom-
ponent of complement so that further lowering of C4 occurs
during episodes of swelling which approaches zero, and C2
levels decrease. This is the main connection between the
bradykinin-forming cascade and complement activation.
New observations requiring more work in terms of their
relationship to HAE include the following1: Prekallikrein is
an enzyme (ie, it stoichiometrically digests the HK to which
it is bound without being converted to kallikrein) and this
reaction is inhibited by C1 INH.32,2 Heat shock protein 90
derived from endothelial cells will interact with the prekalli-
krein-HK complex33 and stoichiometrically convert prekalli-
krein to kallikrein. Thus, initiation of bradykinin formation
and attacks of swelling might result from endothelial cell
activation and HSP 90–dependent conversion of prekalli-
krein to kallikrein and not begin with Factor XII activation.
However, the kallikrein that forms will then activate Factor
XII secondarily so that the normal cascade for bradykinin
generation can proceed. Because complexes of gC1qR-cyto-
keratin 1 and cytokeratin-u-PAR at the cell surface bind
Factor XII and HK (to which prekallikrein is bound) at the
cell surface,34 activation of Factor XII upon binding to
gC1qR (acting as a cell “surface”) can initiate bradykinin
formation in the standard fashion35,36 so that initiation might
involve alterations in the gC1qR-Factor XII interaction. Fur-
ther work along these lines may help elucidate many of the
unknown aspects of HAE—What starts attacks? Why are
they localized to certain areas? Does activation really begin
with Factor XII or does some kallikrein form first? Can
emotional stress really trigger an episode? If so, how?
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